Allen Scott Nielsen on Muck Rack

Allen Scott Nielsen

As seen in: SAGE Publishing, Neurology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Allen Scott

Contact Allen Scott, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in people with relapsing multiple sclerosis who were stable the first year on therapy

|
By Annette M. Langer-Gould, Jessica Smith, Allen Scott Nielsen
| SAGE Publishing
Abstract Data availability statement References Supplementary Material Get access More Cite Share options Information, rights and permissions Metrics and citations Abstract Background: Higher cumulative rituximab doses are associated with greater risks of infections. Therefore, we routinely extend low-dose rituximab (500 mg) intervals in people with relapsing multiple sclerosis (pwRMS) from every 6(q6mo) to 12 months(q12mo) to 18(q18mo) and/or 24 months(q24mo).
Open in Who Shared Issue with article?

Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies

|
By Jessica Smith, Derek McFaul, Nektar N. Hakopian, Allen Scott Nielsen
| Neurology Verified
Abstract Objective To determine whether MS disease-modifying therapies (DMTs) can be safely discontinued in patients aged 50 years or older with suspected benign/burnt-out MS and to define criteria to identify such patients. Methods We conducted a retrospective cohort study of 136 patients with suspected benign/burnt-out MS who discontinued DMTs from the electronic health record (EHR) at Kaiser Permanente Southern California. Results The majority discontinued an injectable DMT (n = 131, 96%).
Open in Who Shared Issue with article?
See all 2 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified